Literature DB >> 2032474

Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies.

A Meulemans1, B Giroux, P Hannoun, D Robine, D Henzel.   

Abstract

In order to assess the apparent diffusion coefficient of two nitrosoureas (carmustine and fotemustine) in the brain, a model of planar diffusion was used in the rat brain and in rat and human brain biopsies. Drugs were deposed on the brain surface at a constant concentration for 30 min. At the end of the diffusion time, the concentration gradient was determined with microelectrodes using voltammetry at 5 different depths in the extracellular space of the gray matter (0-304 microns). Voltammetry with microelectrodes measured quantitatively intact drug in the brain extracellular space (CV 4% for the 2 drugs) in the range studied. The same procedure was used for human and rat brain biopsies which were held in a small cup. The apparent diffusion coefficients in living animals were 0.49 x 10(-6) cm2.s-1 for carmustine and 0.23 x 10(-6) cm2.s-1 for fotemustine; in human biopsies, they were 0.84 x 10(-6) cm2.s-1 for carmustine and 0.37 x 10(-6) cm2.s-1 for fotemustine. Significant differences in the apparent diffusion coefficients of the drugs were accounted for by the fact that the intracellular penetration of fotemustine was better than that of carmustine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032474     DOI: 10.1159/000238838

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  11 in total

1.  Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.

Authors:  Alessandra Fabi; Giulio Metro; Antonello Vidiri; Gaetano Lanzetta; Mariantonia Carosi; Stefano Telera; Marta Maschio; Michelangelo Russillo; Isabella Sperduti; Carmine M Carapella; Francesco Cognetti; Andrea Pace
Journal:  J Neurooncol       Date:  2010-03-30       Impact factor: 4.130

2.  Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Authors:  Mario Balducci; Silvia Chiesa; Barbara Diletto; Giuseppe Roberto D'Agostino; Annunziato Mangiola; Stefania Manfrida; Giovanna Mantini; Alessio Albanese; Alba Fiorentino; Vincenzo Frascino; Berardino De Bari; Francesco Micciche'; Fiorenza De Rose; Alessio Giuseppe Morganti; Carmelo Anile; Vincenzo Valentini
Journal:  Neuro Oncol       Date:  2011-10-12       Impact factor: 12.300

3.  Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study.

Authors:  M Balducci; B Diletto; S Chiesa; G R D'Agostino; M A Gambacorta; M Ferro; C Colosimo; G Maira; C Anile; V Valentini
Journal:  Strahlenther Onkol       Date:  2014-01-17       Impact factor: 3.621

4.  A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.

Authors:  Raffaele Addeo; Michele Caraglia; M Serena De Santi; Liliana Montella; Alberto Abbruzzese; Ciro Parlato; Bruno Vincenzi; Marco Carraturo; Vincenzo Faiola; Michele Genovese; Gregorio Cennamo; Salvatore Del Prete
Journal:  J Neurooncol       Date:  2010-08-10       Impact factor: 4.130

5.  Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.

Authors:  Gaetano Corazzelli; Ferdinando Frigeri; Manuela Arcamone; Luigi Aloj; Gaetana Capobianco; Cristina Becchimanzi; Emanuela Morelli; Francesco Volzone; Gianpaolo Marcacci; Filippo Russo; Rosaria De Filippi; Secondo Lastoria; Antonio Pinto
Journal:  Eur J Haematol       Date:  2011-07-31       Impact factor: 2.997

6.  Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.

Authors:  Manuela Porru; Silvia Zappavigna; Giuseppina Salzano; Amalia Luce; Antonella Stoppacciaro; Maria Luisa Balestrieri; Simona Artuso; Sara Lusa; Giuseppe De Rosa; Carlo Leonetti; Michele Caraglia
Journal:  Oncotarget       Date:  2014-11-15

7.  Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.

Authors:  Alessandra Fabi; Giulio Metro; Michelangelo Russillo; Antonello Vidiri; Carmine Maria Carapella; Marta Maschio; Francesco Cognetti; Bruno Jandolo; Maria Alessandra Mirri; Isabella Sperduti; Stefano Telera; Mariantonia Carosi; Andrea Pace
Journal:  BMC Cancer       Date:  2009-03-31       Impact factor: 4.430

8.  Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Authors:  Alba A Brandes; A Tosoni; E Franceschi; V Blatt; A Santoro; M Faedi; P Amistà; M Gardiman; R Labianca; C Bianchini; M Ermani; M Reni
Journal:  Cancer Chemother Pharmacol       Date:  2009-01-24       Impact factor: 3.333

9.  A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.

Authors:  Alessandro Paccapelo; Ivan Lolli; Maria Grazia Fabrini; Giovanni Silvano; Beatrice Detti; Franco Perrone; Giuseppina Savio; Matteo Santoni; Erminio Bonizzoni; Tania Perrone; Silvia Scoccianti
Journal:  J Transl Med       Date:  2012-05-14       Impact factor: 5.531

Review 10.  An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.

Authors:  Giuseppe Lombardi; Patrizia Farina; Alessandro Della Puppa; Diego Cecchin; Ardi Pambuku; Luisa Bellu; Vittorina Zagonel
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.